
Incyclix appoints Kimberly Blackwell to Board of Directors
Esme Needham | December 17, 2025 | Appointment | | Incyclix, board of directors
Incyclix Bio, a cell cycle control company, has announced the appointment of Kimberly Blackwell to its Board of Directors as an independent board member.
Blackwell brings more than 20 years of experience in drug development to the role, including as a leading innovator in oncology. She is Chief Development Officer at Nucleus RadioPharm, a radiopharmaceutical manufacturing and research and development company partnered with the Mayo Clinic. In addition, she founded Key Oncology Consulting, and has guided various early-stage biotechnology companies in the field of precision oncology. She has held senior leadership roles at companies including Zentalis Pharmaceuticals, Tempus AI and Eli Lilly.
Incyclix specialises in the development of precision treatments to tackle cancer. The company has a particular focus on cyclin-dependent kinases (CDKs) and their role in the cell cycle, studying their potential functions as therapeutic targets across many types of tumours. Blackwell’s expertise in oncology will be useful in her new role: she is a former Duke University Cancer Institute faculty member, has led more than 50 clinical trials, and co-founded radiotherapeutics company Cereius.
“Incyclix’s pioneering work exploring CDK2 inhibition has exciting potential to improve outcomes for patients with treatment resistant and advanced cancer,” said Blackwell.
Patrick Roberts, CEO and co-founder of Incyclix, added: “Dr Blackwell is a distinguished leader in breast cancer research with a breadth of experience advancing multiple oncology programmes through the clinic.”
Related Content

Allergan shareholders reject proposal to split roles of chairman and CEO
Allergan shareholders have rejected a proposal to immediately separate the roles of CEO and chairman, …






